Search Results
Feb 26, 2026, 08:00 ET SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
testing, and packaging.We support the successful market launch of protein- and antibody-based biologics and biosimilars, including vaccines, gene and immune therapeutics, oncolytic viruses, and other sterile injectables that help prevent and treat diseases worldwide.About VaxxasVaxxas
More news about: SK bioscience
Feb 26, 2026, 08:00 ET Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
sevasemten on safety, biomarkers of muscle damage and function in 6- to 14-year-old participants with Duchenne who have been previously treated with gene therapy. The Company will continue to collect longer-term safety and functional data in the open-label extensions of LYNX and FOX while it plans for
More news about: Edgewise Therapeutics
Feb 26, 2026, 06:59 ET Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
that the FDA cleared the Company's Investigational New Drug (IND) application for MR-146, an Enriched Tear FilmTM (ETF) Adeno-Associated Virus (AAV) gene therapy candidate targeted to treat people with neurotrophic keratopathy (NK). In December 2025, the Company
More news about: Viatris Inc.
Feb 26, 2026, 06:00 ET Ecovyst Reports Fourth Quarter and Full Year 2025 Results
https://investor.ecovyst.com/events-presentations.Investor Contact:Gene Shiels(484) 617-1225 [email protected]
More news about: Ecovyst Inc.
Feb 26, 2026, 04:04 ET Scantox Acquires DuplexSeq™ Nonclinical Genomics Safety Business from TwinStrand Biosciences
at global CRO scale across both service and product offerings. The addition complements Scantox's exclusive rights to the Big Blue® transgenic rodent gene mutation assay portfolio, creating an integrated genomic safety platform spanning early screening through late-stage development."Our customers
More news about: Scantox Group
Feb 26, 2026, 04:04 ET Scantox Acquires DuplexSeq™ Nonclinical Genomics Safety Business from TwinStrand Biosciences
at global CRO scale across both service and product offerings. The addition complements Scantox's exclusive rights to the Big Blue® transgenic rodent gene mutation assay portfolio, creating an integrated genomic safety platform spanning early screening through late-stage development."Our customers
More news about: Scantox Group
Feb 26, 2026, 03:15 ET genOway: Revolution der Vorhersage von Antikörpertherapien beim Menschen mit einem einzigartigen Mausmodell
genO–hFcγR-Modell baut auf einem früheren Mausmodell auf, das 2008 von genOway und seinen wissenschaftlichen Partnern entwickelt wurde und in dem mehrere FcγR-Gene humanisiert wurden. Seit seiner Einführung in die wissenschaftliche Gemeinschaft 2024 wurde genO-hFcγR zur Förderung präklinischer Programme von biopharmazeutischen
More news about: genOway
Feb 25, 2026, 21:00 ET Argo Biopharma to Present Positive Phase II Interim Results of siRNA Therapeutic BW-20805 for HAE at the 2026 AAAAI Annual Meeting
treatments require frequent dosing, highlighting the need for long-acting, preventive therapies. BW-20805 targets human hepatic PKK mRNA to inhibit PKK gene expression, offering the potential for effective prevention of HAE attacks with a significant and longer-lasting therapeutic effect.About
More news about: Argo Biopharmaceutical Co., Ltd
Feb 25, 2026, 19:29 ET WOODWARD PARK PARTNERS EXPANDS TEAM WITH ADDITION OF JACK DIFRANCO
market throughout his decades-long career. He is highly respected amongst his peers and has served as a mentor to many M&A professionals," said Gene Bitonti, Co-Founder & Managing Director at Woodward Park Partners. "The addition of Jack to our team will create new opportunities, fueling growth
More news about: Woodward Park Partners
Feb 25, 2026, 18:16 ET Differing immune responses in infants may explain increased severity of RSV over SARS-CoV-2
technologies using advanced computational methods enabled us to not only identify immune response signatures in specific immune cell types but also associate gene expression with potential epigenetic regulators," said co-first author Asa Thibodeau, PhD, Associate Computational Scientist at JAX. "Understanding
More news about: St. Jude Children's Research Hospital
Feb 25, 2026, 17:31 ET Tinnitus Treatment Landscape Set for Significant Market Upswing During Forecast Period (2026-2036) as Need for Effective Therapies Intensifies | DelveInsight
and unmet need, a first-in-class drug providing meaningful, durable symptom reduction could transform the market. Breakthrough therapies, including gene or regenerative approaches, are expected to command premium pricing and drive significant growth opportunities in the coming years.Tinnitus
More news about: DelveInsight Business Research, LLP
Feb 25, 2026, 10:45 ET Age Related Macular Degeneration Market to Reach $16.2 billion by 2033, Globally, by 2034 at 5% CAGR: Allied Market Research
diagnosis, proper treatment, and lifestyle adjustments can significantly decrease its progression. Ongoing research into advanced therapies, including gene therapy and longer-acting anti-VEGF drugs, offers hope for improved management in the future.Rise in number of elderly individuals is a major
More news about: Allied Market Research
Feb 25, 2026, 09:40 ET Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
California to fund stem cell and gene therapy research with the goal of accelerating treatments for patients with unmet medical needs. With $8.5 billion in funding allocated through both Proposition 71 in 2004 and Proposition 14 in 2020, CIRM supports stem cell and gene therapy discoveries from inception
More news about: MAHZI Therapeutics
Feb 25, 2026, 09:15 ET Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
Researchers found more than 2000 unique transcripts in each cell, showing an unprecedented level of sensitivity."Each tumor is unique and its gene expression is never uniform," said Cande Rogert, vice president and global head of advanced sciences at Illumina. "By interrogating a large
More news about: Illumina, Inc.
Feb 25, 2026, 09:00 ET Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc.(RGNX)
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: Levi & Korsinsky, LLP
Feb 25, 2026, 09:00 ET Foundation Fighting Blindness to Host Free Webinar on Regenerative Medicine Advances for Retinal Diseases
development leader within the ophthalmology therapeutic area at BlueRock Therapeutics. Prior to joining BlueRock, Dr. Beasley worked at AGTC, advancing gene therapy assets for inherited retinal degenerations, including retinitis pigmentosa, X-linked retinoschisis, and achromatopsia. She also held clinical
More news about: Foundation Fighting Blindness
Feb 25, 2026, 08:30 ET Pharma is Losing $250 Billion to Patient Dropout. Here's How to Stop It.
the drug to work. Three forces are driving this crisis:Complex therapies dominate new approvals. Biologics, injectables, gene therapies, rare disease and other complex treatments are starting to lead new FDA approvals— each requiring intensive, ongoing patient education.
More news about: Hoot Health, Inc.
Feb 25, 2026, 08:07 ET P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments
Fondazione Telethon to provide U.S. access to an FDA-approved gene therapy, WASKYRA™, via an entirely non-profit-led pathway.OTXL also formed a strategic joint venture in January 2026 with the American Society of Gene & Cell Therapy (ASGCT) to launch CGTxchange, a jointly owned
More news about: Orphan Therapeutics Accelerator
Feb 25, 2026, 08:00 ET Immunexpress Announces Publication Demonstrating SeptiCyte RAPID® Utility for Differentiating Infection from Sterile Inflammation in Readmitted Bone Marrow Transplant Patients with Febrile Neutropaenia
FindingsElevated SeptiScores® were associated with clinically adjudicated infection, supporting the robustness of host-response gene expression despite the inflammatory effects of surgery, treatments and haematologic disease.SeptiCyte performance was preserved across haematologic
More news about: Immunexpress, Inc.
Feb 25, 2026, 07:45 ET Singular Genomics at AGBT 2026: Population-Scale Spatial Takes Center Stage G4X Launch, SPOT-Met Initiative
SPOT-Met, perhaps the world's largest in situ multiomic initiative to-date in colorectal cancer; the company also showcases platform validation data, 1,300-gene plex capability, and in situ sequencing of FFPE samples (Direct-Seq™).ORLANDO, Fla., Feb.
More news about: Singular Genomics
Feb 25, 2026, 07:18 ET Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
the interleukin-36 (IL-36) pathway.1 The majority of GPP cases for which a causal single gene defect has been identified are caused by various consequential genetic variants in the IL36RN gene, encoding the IL-36 receptor antagonist (IL-36Ra).2,3,4Imsidolimab is a fully humanized
More news about: Vanda Pharmaceuticals Inc.
Feb 25, 2026, 07:05 ET REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
recognizing this important preclinical work."DM1 is a multisystemic, RNA-mediated genetic disorder caused by expanded CTG repeats in the DMPK gene, leading to toxic RNA transcripts that disrupt post-transcriptional regulation. A central pathogenic mechanism is the depletion of Muscleblind-like (MBNL)
More news about: ARTHEx Biotech
Feb 25, 2026, 00:02 ET Children's Hospital of Philadelphia Marks One-Year Anniversary of World's First Personalized CRISPR Gene Therapy for Child with Rare Genetic Disease
Editing Consortium. Currently, CHOP supports more than 80 faculty advancing cell and gene therapy across more than 20 programs and 45 active pediatric clinical trials."We're just beginning to unlock gene editing's potential in pediatrics and beyond," said
More news about: Children's Hospital of Philadelphia
Feb 24, 2026, 18:52 ET QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages QURE Investors with Losses to Contact the Firm
SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD. During
More news about: Kessler Topaz Meltzer & Check, LLP